Earnings call transcript: Inspiration Healthcare posts record H2 2026 results

Inspiration Healthcare delivered record FY2026 results, with revenue up 24% to GBP 49m-plus, EBITDA rising to GBP 2.8m from GBP 200k, and operating cash inflow of GBP 7.5m as net debt fell to GBP 5.1m. Revenue met consensus at $23.5m, but investors focused on margin improvement, inventory reduction, and a stronger outlook for FY2027, sending the stock up 4.81%. Management highlighted U.S. market entry, consumables, and service expansion as key medium-term growth drivers, while maintaining a long-term EBITDA margin target of at least 15%.

Analysis

The setup is less about a clean top-line beat and more about a mix shift that can re-rate the equity if management executes. The market is paying for evidence that the business is moving from lumpy project dependence toward recurring, higher-margin consumables and service, while also proving it can convert earnings into cash. That matters because the cash swing and debt reduction lower financing risk just as the company is asking investors to underwrite a multi-year U.S. option.

The hidden second-order issue is the near-term profit bridge. The announced transfer of the infusion business creates a mechanically harder FY2028 comparison right when the company is trying to prove it can scale the rest of the platform. That means the shares may continue to trade well on momentum and narrative over the next 6-12 months, but the multiple should be capped unless recurring revenue inflects sooner than expected and new product launches actually expand gross margin rather than just defend it.

Consensus is probably underestimating how much of the current optimism is already pulled forward in the stock. After a large run and a valuation near the top of the range, the next leg likely needs either an acceleration in consumables attach rates or a credible acquisition that shortens the U.S. timeline. The main downside case is not demand collapse; it’s a sequence of delayed FDA timing, slower-than-promised consumables adoption, and the loss of infusion contribution creating a margin air pocket before the U.S. revenue option turns on.

Key Decisions for Investors

• Long SLE on pullbacks over the next 2-6 weeks; use a starter position only, because the chart has already discounted a lot of operational improvement. Risk/reward is attractive if the market continues to pay for recurring-revenue optionality, but take profits into any further 15-20% leg higher unless consumables traction is explicitly improving.
• Buy 3-6 month call spreads on SLE rather than outright stock to express upside tied to execution on consumables and Airon follow-through. Favor structures that monetize another rerating without overpaying for the longer FDA timeline.
• Pair trade: long SLE / short a more mature medtech distributor with lower recurring-revenue conversion. The thesis is that SLE’s mix shift and operating leverage can outperform pure distributors over the next 2-4 quarters even if headline growth normalizes.
• If holding SLE into FY2028, hedge with medium-dated puts or trim into strength; the infusion transfer creates a foreseeable earnings air pocket that could compress the multiple before U.S. access arrives.
• Watch for an entry point on any post-rally consolidation after the consumables launch cadence is confirmed; if the stock fades on no volume, that is likely a better risk/reward setup than chasing strength near the range high.